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Approximately 100 different human pharma-
ceuticals have been identiﬁed at low levels in
wastewater treatment plant efﬂuents, surface
waters, seawaters, groundwater, and some
drinking waters from around the world (Fent
et al. 2006; Hemminger 2005; Kolpin et al.
2002). Classes of drugs that have been
detected include analgesics and anti-inﬂamma-
tories, beta-blockers, lipid regulators, anti-
epileptics, anti-depressants, oral contraceptives,
and antibiotics. Intentional ﬂushing of medica-
tions down the toilet, rinsing topically applied
medications off in the tub or sink, and excre-
tion of medications in urine or feces are the
entry points for most pharmaceuticals into
wastewater treatment systems. The federal gov-
ernment and a number of states have discour-
aged disposal of drugs by ﬂushing them down
the toilet, but this does not prevent contami-
nation by rinsing or excretion. Although there
are no documented health consequences from
these exposures, there are concerns about the
impact of long-term low-level exposures to
medications, especially those that are environ-
mentally persistent, and those that may bio-
accumulate in the food chain. Impacts on
ecologic systems are also of concern, especially
in light of discovery of intersex ﬁsh in major
waterways in the United States and their asso-
ciation with exposure to endocrine disruptors
(Chambers and Leiker 2006). Advanced water
treatment technologies can remove many
contaminants; however, this technology is
expensive and may not be affordable for many
municipalities. As communities look for alter-
native ways to manage pharmaceuticals and
persistent chemicals in wastewater, the
California ban on lindane deserves scrutiny as
a potential approach to improve wastewater
quality and limit global contamination with
persistent organic pollutants (POPs). 
Lindane, the gamma isomer of hexachloro-
cyclohexane (γ-HCH), is an environmentally
persistent organochlorine insecticide manufac-
tured since the 1940s for both agricultural and
pharmaceutical purposes. In agriculture, lin-
dane has been used as an insecticide to treat
seeds, crops, and lumber/timber, and to treat
cattle and other farm animals for ectoparasites.
As a prescription medication, lindane is used as
a topical treatment for human infestations of
head lice and scabies.
Throughout the world, recognition of lin-
dane’s toxicity and its environmental persis-
tence has resulted in an overall decline in use.
Lindane has not been produced in the United
States for many decades and has undergone
progressive limitations on agricultural use
[Commission for Environmental Cooperation
(CEC) 2006]. In August 2006, the U.S.
Environmental Protection Agency (EPA) can-
celled all remaining registrations for agricul-
tural uses of lindane (U.S. EPA 2006). 
When used as a pharmaceutical, acute
exposure to lindane has been reported to cause
skin irritation, dizziness, headaches, diarrhea,
nausea, vomiting, and, in some instances, con-
vulsions and death (Thomson Micromedex
2006). There have been 3 confirmed deaths
and 17 reported deaths associated with lin-
dane use [Food and Drug Administration
(FDA) 2003c]. All of the deaths occurred
when lindane was used in an off-label manner.
Neurologic effects are commonly reported
outcomes in the FDA adverse effects database
(FDA 2003c). Of the reported neurologic
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INTRODUCTION: There are increasing concerns over the presence and implications of pharmaceutical
agents in water. In 2002, California banned pharmaceutical use of lindane because of concerns
about water quality, as lindane treatment for head lice and scabies was found to be a signiﬁcant fac-
tor adversely affecting wastewater quality. 
OBJECTIVES: In this article we describe the effects the ban has had on wastewater quality, uninten-
tional exposures, and clinical practice. This is the ﬁrst time that a pharmaceutical has been out-
lawed to protect water quality. As such, this ban provides a rare opportunity to evaluate the possible
or potential outcomes of future public health interventions aimed at reducing pharmaceutical water
contamination. 
METHODS: We compiled data on lindane in wastewater treatment plant efﬂuent for several large
plants in California and one outside of California. Data on exposures to lindane were obtained
from records of the California Poison Control System. We assessed the impact on clinical practice
via a survey of 400 pediatricians. 
RESULTS: Wastewater treatment plant monitoring showed that lindane declined in California
after the ban. Similarly, unintentional exposure calls declined. Most physicians were aware of the
ban (81%) and had used lindane previously (61%), but they did not notice any difﬁculties with the
ban (78%). 
CONCLUSIONS: The California experience suggests that elimination of pharmaceutical lindane pro-
duced environmental beneﬁts, was associated with a reduction in reported unintentional exposures,
and did not adversely affect head lice and scabies treatment. This ban serves as a model for govern-
ing bodies considering limits on the use of lindane or other pharmaceuticals.
KEY WORDS: contamination, head lice, lindane, persistent organic pollutant, pharmaceutical, physi-
cian survey, scabies, unintentional ingestions, wastewater. Environ Health Perspect 116:297–302
(2008). doi:10.1289/ehp.10668 available via http://dx.doi.org/ [Online 11 December 2007]events, 70% included seizure, dizziness,
headache, and paresthesias (FDA 2003c). In
some instances, lindane has caused seizures
after one application given according to pack-
age directions (FDA 2003a, 2003b).
Lindane is the least effective common
pharmaceutical treatment for head lice when
compared in vitro with other chemical alterna-
tives including pyrethroids, malathion, or syn-
ergized pyrethrins (Meinking et al. 2002).
Because of toxicity concerns, in 1995 the FDA
advised that lindane be labeled as second line
therapy, only to be used after other treatments
have failed (FDA 2003c). In 2003, the FDA
issued a “black box” public health warning for
lindane treatments, reemphasizing that lindane
should only be used as second line therapy and
recommending use with caution in anyone
weighing < 110 lb, the elderly, and those with
seizure disorders (FDA 2003c). Despite the
cancellation for agricultural use, demonstrated
toxicity in humans, and low efﬁcacy in treating
pediculosis (Meinking et al. 2002), lindane
continues to be available by prescription in the
United States.
Lindane is a known contaminant in waste-
water. Because head lice and scabies treat-
ments are rinsed down the drain after use,
lindane readily enters wastewater treatment
plants. Wastewater treatment plants are not
designed to remove lindane; therefore, much
of the lindane passes through and enters
downstream lakes, rivers, and the ocean (U.S.
EPA 2002). California has stringent water
quality standards for lindane, including a cri-
teria of 19 ppt for existing or potential drink-
ing water sources (U.S. EPA 2000). This
standard is based on long-term human cancer
risk from ingestion. Wastewater treatment
engineers in Los Angeles, California, calcu-
lated that a single treatment for head lice or
scabies contains enough lindane to bring
6 million gallons of water above this
California water quality standard [County
Sanitation Districts of Los Angeles County
(CSDLAC) 2001]. To address these concerns,
the CSDLAC, the City of Los Angeles, and
the National Pediculosis Association jointly
conducted an outreach campaign in 1999 to
provide information to clinicians on alterna-
tives to lindane and to recommend limiting its
use (CSDLAC 2000). The outreach campaign
consisted of three direct mailings to target
audiences and mass-media exposure. Direct
mailings included ﬂyers (in seven languages),
refrigerator magnets, and head lice combs.
Presentations were made addressing the issues
of the campaign. Mass media included news-
paper, radio, and television coverage. The tar-
get audiences included doctors, hospitals,
pharmacists, school nurses, and day care cen-
ters in Long Beach and Burbank, California. A
relevant website and a toll-free hotline were
also established.
In 2000, the California legislature passed,
with no opposition on record, a ban on the
sale of all pharmaceutical lindane products
effective 1 January 2002 (State of California
2000). To determine the potential impact of
this ban on water quality, we obtained data
from wastewater treatment plants on waste-
water lindane concentrations. Also, to deter-
mine the number of acute poisonings due to
lindane before and after the ban, we reviewed
telephone calls to the California Poison
Control System. To more systematically
investigate the impact of the lindane ban on
prescribing practices of health care providers’
in California, we surveyed pediatricians
3 years after the ban’s effective date. 
Methods
Wastewater concentrations. We examined
annual mean concentrations of lindane (in parts
per trillion) for several large treatment plants in
California. Historical water-lindane concentra-
tions were obtained directly from the following
California agencies: CSDLAC’s Joint Water
Pollution Control Plant, serving > 3 million
people in Los Angeles County; the City of Los
Angeles’ Hyperion Treatment Plant, also serv-
ing > 3 million people in Los Angeles County;
the Plants 1 and 2 of the Orange County
Sanitation Districts, serving 2.5 million people
in Orange County; and the San Jose/Santa
Clara Water Pollution Control Plant, serving
1.5 million people in Santa Clara County.
Concentrations of lindane entering the plants
were examined except for the San Jose/Santa
Clara Water Pollution Control Plant, where
adequate data were not available. For that treat-
ment plant, we examined concentrations of lin-
dane exiting the plant. Because lindane is not
widely analyzed at wastewater treatment plants
outside of California using sensitive analytical
methods, limited wastewater lindane data is
available outside of California for comparison.
However, we obtained data for the Clermont
County Sewer District’s Middle East Fork
Wastewater Treatment Plant, serving approxi-
mately 30,000 people in Clermont County,
Ohio. Routine monitoring of wastewater for
lindane at these treatment plants was performed
monthly or quarterly, and was based on sam-
ples taken over a 24-hr period. 
California Poison Control System calls and
prescribing trends for lindane. We searched the
California Poison Control System case
management database using Visual Dotlab,
version 4.3.1 (WBM Software, Fresno, CA) for
years 1998–2006 for calls related to uninten-
tional exposures to lindane. We used product-
specific codes from Poisindex (Thomson
Healthcare 2007) for personal care products
containing lindane to identify 21 shampoos,
creams, and lotions. A tally of annual calls
related to all unintentional exposures was
obtained as a denominator.
To examine lindane prescribing trends in
California, Medi-Cal fee-for-service pharmacy
paid claims data for lindane were compiled
for the fiscal years 1997–2002 (California
Department of Health Services 2007).
Nationwide data on the total number of
lindane prescriptions by calendar years
1997–2006 were also compiled (Verispan
Inc. 2007).
Survey. We developed a written survey to
elicit information about characteristics of
provider practices, provider awareness and
perception of the California lindane ban, and
current treatment preferences for head lice and
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Figure 1. Mean lindane concentrations at four California wastewater treatment plants: Joint Water
Pollution Control Plant (JWPCP), Hyperion Treatment Plant (HTP), Orange County Sanitation Districts’
Plants 1 and 2 (OCSD), and San Jose/Santa Clara Water Pollution Control Plant (SJSC). All data are for
inﬂuent except for SJSC, which are for efﬂuent. The California standard for lindane in surface water bod-
ies that are existing or potential drinking water sources is 19 ppt. Arrows indicate when permethrin
became OTC (1990), the outreach campaign in Los Angeles County began (1999), and the ban was passed
(2000); the ban took affect in 2002 (dashed line). 
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Yearscabies. We obtained approval from the
Committee on Human Research at the
University of California, San Francisco, prior
to mailing the survey. Among a population of
4,179 non-emeritus members of the American
Academy of Pediatrics, California district,
400 members were selected at random to
receive the survey. Each selected participant
was mailed three separate surveys with a return
envelope 1 month apart. We analyzed the data
using Stata, version 9 (StataCorp, College
Station, TX).
Results
Wastewater concentrations. Before Los
Angeles County outreach efforts on pharma-
ceutical lindane began in 1999, the average
wastewater concentration of lindane was
36 ppt. Although the concentration has
declined steadily since that time, it remained
elevated at several major California wastewater
treatment plants at the time the lindane ban in
California was enacted. By 2006, 4 years after
the ban took effect, lindane concentrations
had dropped to almost undetectable concen-
trations in California. There is limited avail-
ability of lindane wastewater data outside of
California, but data from one Ohio treatment
plant (Clermont County Sewer District’s
Middle East Fork Wastewater Treatment
Plant, Batavia, OH) indicates that lindane
concentrations remained signiﬁcantly elevated
in Ohio after the California ban was enacted.
Figure 1 shows the mean concentration of
lindane at the California treatment plants. 
California Poison Control System expo-
sure calls and prescribing trends for lindane.
In 1998, there were 135 calls reporting unin-
tentional lindane exposure per 100,000 calls
to the California Poison Control System.
This volume declined somewhat in 2001
(50 calls/100,000) and then fell to near zero in
the years following the ban (2 calls/100,000
per year for 2004–2006). Figure 2 shows
annual calls to the California Poison Control
System for 1998–2006 for unintentional expo-
sures related to lindane. 
Prescriptions for lindane filled by the
Medi-Cal state insurance program dropped
from > 114,000 in 1997 to 11,366 in 2001
and 34 in 2002 (reﬂecting delayed payment for
pre-ban prescriptions) paralleling the decline in
wastewater concentrations (Figure 3).
Nationwide prescriptions for lindane during
the same period declined similarly. In January
2002 California sales ended abruptly, coincid-
ing with the ban. In contrast, since 2002 the
rate of decline in national sales has slowed, as
illustrated in Figure 3.
Surveys. Of the 400 mailed surveys,
171 (43%) were returned after three mailings.
No information was available for the non-
responders. Thirty-two surveys from non-
practicing physicians were excluded from the
ﬁnal analysis. In addition, 4 incomplete sur-
veys were dropped from the group. The
analysis was performed on the remaining
135 responses. 
Responder characteristics. Table 1
describes the practice characteristics of the
respondents. The majority (77%) of respond-
ing health providers practiced > 30 hr/week.
Over one-half (55%) of the pediatricians
practiced in a group private practice, 14%
were in a health maintenance organization
setting, and 13% of respondents were in solo
practice. Approximately one-half (53%) of
respondents were in practice for < 15 years. 
Pediatricians differed substantially in the
number of cases of head lice and scabies they
typically manage in their practice. For head
lice, 70 respondents (52%) reported manag-
ing 3–14 cases in the last 3 months, and 60
respondents (45%) managed < 2 cases; only
3% of the providers managed > 15 cases of
head lice in the last 3 months. Similarly, for
scabies, 50 pediatricians (37%) managed
between 3 and 14 cases of in the last
3 months, and 79 (59%) managed ≤ 2 cases;
only 4% managed > 15 cases of scabies in the
last 3 months.
Response to lindane ban. More than one-
half (61%) of pediatricians reported using lin-
dane before the ban, and the vast majority
(81%) were aware of the ban. Of the providers
who reported using lindane prior to the ban,
virtually all (94%) reported changing their pre-
scribing practices as a result of the ban. 
Most respondents (78%) did not notice
any difficulties after the lindane ban.
However, 30 providers did report difﬁculties
after the ban. Of these, most used lindane
before the ban (26 of 30; 87%) and only 4 of
30 did not report prior lindane use. Those
providers who reported that they had used
lindane pre-ban and noticed difﬁculties after
the ban were far more likely to be in solo pri-
vate practice (35% vs. 7%) and to have been
in practice > 15 years (58% vs. 44%).
Providers reporting difficulty after the ban
cited resistant lice as the main reason (97%);
however, overall reports of resistant scabies
were minimal (5%), as were increased cases of
lice (7%) or scabies (1%). There were no sig-
nificant differences among volume of head
lice or scabies cases seen in the previous
3 months between providers who reported
difﬁculties and those who did not.
Treatment preferences. The majority of
respondents (69%) stated their ﬁrst-line treat-
ment preference for head lice was 1% perme-
thrin, followed by 5% permethrin (9%) and
other over-the-counter (OTC) methods
including pyrethrum (8%). Respondent prefer-
ence for second-line head lice treatment was
malathion (51%), followed by 5% permethrin
(19%). For scabies treatment, the majority
(92%) of respondents expressed preference for
5% permethrin (92%), followed by crotamiton
(5%). Second-line treatment preference for
scabies included crotamiton (32%), followed
by 5% permethrin (25%), malathion (21%),
and others (22%).
Discussion
Wastewater concentrations. Because there was
little to no agricultural use of lindane in
urban areas of California, elevated wastewater
concentrations of lindane were attributed to
pharmaceutical lindane usage (CSDLAC
2001). 
As Figure 1 illustrates, average concentra-
tions of lindane were declining after 1991,
paralleling reductions in prescriptions ﬁlled in
California by Medi-Cal (Figure 3) and likely
reﬂecting the availability of effective and safe
Outcomes of the California ban on pharmaceutical lindane
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Table 1. Pediatrician survey respondent charac-
teristics.
No. (%)
Practice type
Solo 17 (13)
Group or private 74 (55)
Health maintenance organization 19 (14)
Federal, military, or public 7 (5)
Academic 11 (8)
Other 7 (5)
Hours practiced per week
≥ 30 104 (77)
< 30 31 (23)
Years in practice
≥ 15 63 (47)
< 15 72 (53)
Figure 2. Annual number of calls regarding unin-
tentional exposures to lindane per 100,000 calls,
1998–2006. 
Data from the California Poison Control System.
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NationalOTC alternatives. Permethrin, for instance,
was first available in 1986 and made OTC
status in 1990. Although we were unable to
establish historical retail prices of lindane, the
lowest average wholesale price (AWP) of lin-
dane shampoo relative to that of permethrin
went from 20% to 110% from 1990 to 1999
(Kapusnik-Uner J, personal communication).
In addition to the introduction of alternative
treatments and public health advisories, medi-
cal treatment recommendations in the litera-
ture and price increases of lindane may have
also contributed to the gradual decline in use
of lindane.
After the pharmaceutical lindane ban went
into effect, lindane concentrations at California
wastewater treatment plants dropped to essen-
tially nondetectable levels. Although there is
limited data available outside of California for
comparison, one Ohio wastewater treatment
plant demonstrated signiﬁcantly elevated lin-
dane concentrations after the California ban
was enacted. This suggests that the ban played
a major role in the decreased California waste-
water concentrations relative to other factors,
such as the cost of pharmaceutical lindane and
availability of alternatives.
Unintentional ingestion and prescribing
trends for lindane. Lice and scabies infesta-
tions are a worldwide problem, and are espe-
cially prevalent in institutions such as schools,
prisons, and nursing homes. Infestations are
usually not life-threatening, but they can be
persistent and recurring, and they can cause
considerable frustration and embarrassment
in families. Whereas lindane was once an
inexpensive and effective treatment, it is now
more expensive than many alternatives (West
2004) and has been associated with wide-
spread resistance throughout the world
(Heukelbach and Feldmeier 2006; Ko and
Elston 2004). 
A recent report shows that prescriptions for
lindane in the United States have declined by
87% over the last 12 years (U.S. EPA 2007).
Yet, there were 242,000 prescriptions written
for lindane in 2005 (U.S. EPA 2007) and
> 186,000 in 2006 (Verispan Inc. 2007), and
870 unintentional ingestions of lindane
occurred in the United States during the 5-year
period 1998–2003 [Centers for Disease
Control and Prevention (CDC) 2005b].
Although there was a dramatic decline in lin-
dane prescriptions ﬁlled under the Medi-Cal
program in California in the 5 years prior to
the ban, there were still > 11,000 ﬁlled in the
year before the ban. Despite lindane’s use as a
second-line drug, unintentional ingestions
from lindane were more likely to produce ill-
ness than ingestions of all alternative medica-
tions combined (pyrethrin/piperonyl butoxide,
permethrin, and malathion) (CDC 2005b). In
contrast, calls related to lindane exposure to the
California Poison Control System declined
gradually from 1998 to 2002, but went to
near zero after the ban. This information
highlights the fact that, although the pharma-
ceutical use of lindane in states other than
California has declined, there is still a signiﬁ-
cant volume of use and continued morbidity
from unintentional exposures. 
Summary of survey results. Three years
after pharmaceutical use of the pesticide lin-
dane was banned in California, our survey of
practicing California pediatricians indicated
that > 80% of physician respondents were
aware of the ban, and a similar majority
reported no difficulties complying with the
ban. Despite outreach efforts by the State
Department of Health Services and county
public health officials, nearly two-thirds of
pediatricians were prescribing lindane at least
occasionally before the ban and had to change
their prescribing practices as a result of the
ban. The minority of providers who were
using lindane and noticed difﬁculties after the
ban were more likely to be in solo practice
and to have been in practice > 15 years, sug-
gesting a subpopulation of pediatricians who
may beneﬁt from education about alternative
treatments for head lice and scabies. There
was concordance among providers for current
ﬁrst line treatments for head lice and scabies.
Most providers did not report an increase
in resistance of lice or scabies following the
ban on lindane. One limitation of our survey
is that it was not sensitive enough to dis-
tinguish between an increase in resistance pre-
dating the ban from any additional resistance
temporally associated with the ban or thought
to be related to the ban. Most chemical treat-
ments for pediculosis will result in resistance
over time (Downs 2004). Written comments
on our survey from providers suggest that
either there was no additional increase in resis-
tance after the ban or that any increase was
unrelated. For instance, written responses
from providers included these comments:
“there seems to be an inexplicable decrease in
both infestations”; “I think resistance and
ban of Kwell are entirely unrelated”; and
“only seeing rare clinical challenges now.” As
well, the California Department of Public
Health has not identified an impact of the
ban on either head lice or scabies outbreaks
(Husted S, personal communication).
This study is, to our knowledge, the ﬁrst
evaluation of the clinical and environmental
effects of the California lindane ban. The
main limitation of our survey was a survey
response < 50%, although this response rate is
similar to that from other published studies
using mailed surveys (Asch et al. 1997;
McMahon et al. 2003). There is no informa-
tion about the nonresponders. This low
response rate could introduce bias. For exam-
ple, if providers who experienced problems
were more likely to respond to the survey, this
would have overestimated reported difﬁculties
following the lindane ban. 
Alternatives to lindane for head lice/scabies
treatment. The current recommended ﬁrst-line
treatment for head lice is OTC 1% permethrin
(Frankowski and Weiner 2002). Pediatricians
in the California survey generally seemed to be
aware of this and adhere to the guidelines. A
recent Cochrane Review (Dodd 2001) found
no evidence that any one pediculocide, includ-
ing malathion, permethrin, and synergized
pyrethrins, was more effective than another,
although only 4 of 71 randomized, placebo-
controlled studies met the inclusion criteria.
Oral ivermectin has also been used when topi-
cal treatments cannot be used or when all other
therapies have failed, although it is currently
not FDA approved for this use (The Medical
Letter 2005). 
A complete review of alternatives for the
treatment of head lice and scabies is beyond
the scope of this article; however, several
recent publications provide such a discussion
(Jones and English 2003; Karthikeyan 2005;
Meinking 2004; Walker and Johnstone
2000). Several recent uncontrolled studies on
nonchemical treatments for head lice—relying
on suffocation and desiccation—also show
promise (Goates et al. 2006; The Medical
Letter 2005; Pearlman 2004). In another
recent small single-blinded, randomized study
comparing common pediculocides to wet
combing (nit removal by using a fine-
toothed comb through wet hair), Hill et al.
(2005) found wet combing to be effective.
These methods are preferable because they
are not toxic to humans or the environment
and are not susceptible to the development
of resistance. 
Environmental concerns. Currently, lin-
dane may only be sold in the United States
for use as a second-line treatment for head lice
and scabies. However, the continued use and
production of lindane raises international
environmental pollution concerns and ethical
issues.
For every ton of lindane that is produced,
approximately 9 tons of toxic waste by-products
are generated (CEC 2006). Lindane is the
γ-isomer of HCH and is isolated from a mix-
ture of eight isomers in technical-grade HCH
(CEC 2006). None of the other HCH iso-
mers are used commercially, and several are
significantly more toxic and persistent than
lindane itself, creating a disposal problem that
has been poorly managed in many countries.
Lindane production and use has resulted in
contamination of products signiﬁcant to chil-
dren, such as butter and milk (Pardio et al.
2003; Waliszewski et al. 2003). In both ani-
mal and human studies, lindane and other
HCH isomers have been associated with toxic
health effects, including neurotoxicity,
increased cancer risk, reproductive harm, and
Humphreys et al.
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Substances and Disease Registry 2005;
International Agency for Research on Cancer
1998). Although long lived in the environ-
ment, studies have shown that in countries
that have restricted or banned lindane, levels
of HCH in breast milk have declined over
time (Jensen and Slorach 1991; Konishi et al.
2001; Schade and Heinzow 1998). Similarly,
biomonitoring data from the United States
found levels of lindane below the limits of
detection, and lower than in people from
many other countries (CDC 2005a). The
β-HCH isomers are still found in measurable
concentrations in Americans and were higher
in Mexican Americans (CDC 2005a).
Over the past two decades, there has been
a steady decline in the production and use of
lindane. Worldwide production of lindane is
estimated to have decreased from 38,000 tons/
year in 1986 to approximately 3,222 tons/year
during 1990–1995 (International POPs
Elimination Network 2007). More recent ﬁg-
ures are not available. However, it has been
estimated that between 2 and 4.8 million tons
of HCH waste by-products are present world-
wide (Vijgen 2006). These waste products are
highly persistent chlorinated compounds;
thus, there is no easy and effective way to dis-
pose of them or remediate sites of production,
creating a costly and hazardous situation.
Production of lindane has moved from indus-
trialized to developing countries, which raises
ethical issues because the manufacturing coun-
try becomes the dumping ground for the
waste. Documentation about production is
sparse. Because it is joining the European
Union, Romania is slated to discontinue pro-
duction at the end of 2007. The remaining
lindane production sites are thought to be
only India and China (CEC 2006; Schade and
Heinzow 1998). 
Lindane is registered for use in 17 coun-
tries, has been completely banned in > 50 coun-
tries, and has restricted use in 33 countries
(CEC 2006). In recognition of the global pol-
lution resulting from POPs such as lindane,
there have been international efforts to regu-
late and eliminate these substances. Mexico,
the United States, and Canada, for instance,
have collaborated in the North American
Regional Plan to eliminate or ban the use of
lindane where warranted and reduce the risks
from exposure to HCH isomers (CEC 2006).
In addition, Mexico has nominated lindane
and other HCH isomers as candidates for the
Stockholm Convention, a global treaty to pro-
tect human health and the environment from
POPs.
In summary, there are safer and more
effective treatment alternatives for head lice
and scabies. The experience in California has
resulted in ecologic beneﬁts, including the vir-
tual elimination of lindane from California
wastewater, and in the reduction of uninten-
tional exposure calls to the Poison Control
System. Our survey results suggest that the ban
on the pharmaceutical use of lindane has not
posed a signiﬁcant problem for clinicians. Use
and wastewater contamination did decrease in
California during the years before the ban,
likely resulting from California public outreach
efforts, the FDA advisories, recommendations
in the medical literature, and the availability of
alternatives. However, use continued; it was
ultimately the legislative ban that was corre-
lated with improvements in California waste-
water quality, a decrease in unintentional
exposure calls, and the cessation of clinician
use of lindane. Given the recognition of lin-
dane and other HCH isomers as toxic and per-
sistent chemicals with health consequences,
coupled with the ethical issues of manufactur-
ing in developing countries for use elsewhere,
the harms of use and production may out-
weigh any residual beneﬁt from maintaining it
as a second-line therapy. 
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